$HOTH
Hoth Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000121390024042906 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $1.235B $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.080M $1.588M $1.223M
YoY Change 6.85% 71.32% -30.98%
% of Gross Profit
Research & Development $566.3K $465.9K $914.6K
YoY Change -11.64% -47.7% -37.94%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.646M $2.054M $1.698M
YoY Change -3.67% -6.32% -50.37%
Operating Profit -$1.646M -$2.054M
YoY Change -3.67% -6.32%
Interest Expense $13.37K $13.38K -$3.670K
YoY Change -108.13% 43.72% -99.22%
% of Operating Profit
Other Income/Expense, Net $13.37K $13.38K -$790.00
YoY Change -108.13% 43.66% -100.19%
Pretax Income -$1.632M -$2.041M -$1.702M
YoY Change -12.84% -6.54% -51.06%
Income Tax
% Of Pretax Income
Net Earnings -$1.632M -$2.041M -$1.702M
YoY Change -12.84% -6.54% -51.06%
Net Earnings / Revenue -0.17%
Basic Earnings Per Share -$0.24 -$0.46
Diluted Earnings Per Share -$0.24 -$0.46 -$0.39
COMMON SHARES
Basic Shares Outstanding 4.889M shares 4.404M shares 4.346M shares
Diluted Shares Outstanding 6.876M shares 4.399M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.655M $7.563M $9.292M
YoY Change -16.55% -42.86% 39.99%
Cash & Equivalents $9.655M $7.563M $9.292M
Short-Term Investments $0.00
Other Short-Term Assets $299.7K $843.7K $135.4K
YoY Change -4.82% 335.57% 53.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.955M $8.406M $9.428M
YoY Change -16.24% -37.4% 40.16%
LONG-TERM ASSETS
Property, Plant & Equipment $41.10K $48.22K $55.17K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $36.82K $36.82K $37.40K
YoY Change 11.58% 11.58% 13.33%
Other Assets $85.04K $92.57K
YoY Change
Total Long-Term Assets $77.92K $85.04K $92.57K
YoY Change 136.13% 157.7% 180.52%
TOTAL ASSETS
Total Short-Term Assets $9.955M $8.406M $9.428M
Total Long-Term Assets $77.92K $85.04K $92.57K
Total Assets $10.03M $8.491M $9.520M
YoY Change -15.82% -36.92% 40.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $333.3K $360.9K $35.59K
YoY Change -35.98% -53.9% -94.88%
Accrued Expenses $317.4K $249.6K $643.1K
YoY Change -72.68% -52.91% -3.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $680.8K $639.8K $678.7K
YoY Change -60.33% -52.47% -51.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.04K $18.90K $26.33K
YoY Change -95.58% -92.44% -89.47%
Total Long-Term Liabilities $11.04K $18.90K $26.33K
YoY Change -95.58% -92.44% -89.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $680.8K $639.8K $678.7K
Total Long-Term Liabilities $11.04K $18.90K $26.33K
Total Liabilities $691.9K $658.7K $705.0K
YoY Change -64.81% -58.73% -56.95%
SHAREHOLDERS EQUITY
Retained Earnings -$56.60M -$54.99M -$52.94M
YoY Change 15.14% 16.29% 17.4%
Common Stock $536.00 $440.00 $435.00
YoY Change 62.42% 33.33% 234.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.341M $7.833M $8.815M
YoY Change
Total Liabilities & Shareholders Equity $10.03M $8.491M $9.520M
YoY Change -15.82% -36.92% 40.85%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$1.632M -$2.041M -$1.702M
YoY Change -12.84% -6.54% -51.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.592M -$1.724M -$3.067M
YoY Change 9.8% -24.7% 20.28%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.682M -2.650K
YoY Change -105.2%
NET CHANGE
Cash From Operating Activities -1.592M -$1.724M -3.067M
Cash From Investing Activities 0.000
Cash From Financing Activities 3.682M -2.650K
Net Change In Cash 2.091M -$1.724M -3.070M
YoY Change -244.21% -126.03% 22.47%
FREE CASH FLOW
Cash From Operating Activities -$1.592M -$1.724M -$3.067M
Capital Expenditures $0.00
Free Cash Flow -$3.067M
YoY Change 19.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2482824 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4398909 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38803
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Hoth Therapeutics, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1553794
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
590 Madison Ave
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
21st Floor
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
CY2024Q1 dei City Area Code
CityAreaCode
(646)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
756-2997
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
HOTH
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4888804 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7562628 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9292352 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
293160 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
135361 usd
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
550500 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
8406288 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9427713 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48222 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55165 usd
CY2024Q1 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
36819 usd
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
37400 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
85041 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
92565 usd
CY2024Q1 us-gaap Assets
Assets
8491329 usd
CY2023Q4 us-gaap Assets
Assets
9520278 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
360905 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
35592 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
249608 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
614226 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
29321 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
28839 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
639834 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
678657 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18901 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26326 usd
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
18901 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
26326 usd
CY2024Q1 us-gaap Liabilities
Liabilities
658735 usd
CY2023Q4 us-gaap Liabilities
Liabilities
704983 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 hoth Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3000000 shares
CY2023Q4 hoth Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4403804 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4403804 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4348129 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4348129 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
440 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
435 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62795951 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61732106 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54985289 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52944506 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21492 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
27260 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7832594 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8815295 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8491329 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9520278 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
465896 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
938878 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1588262 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1253939 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
2054158 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2192817 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2054158 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2192817 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-18803 usd
CY2024Q1 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-581 usd
CY2024Q1 us-gaap Dividend Income Operating
DividendIncomeOperating
13956 usd
CY2023Q1 us-gaap Dividend Income Operating
DividendIncomeOperating
28113 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13375 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9310 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2040783 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2183507 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4398909 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2482824 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2040783 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2183507 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5768 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5370 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2046551 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2178137 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8815295 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
513350 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
550500 usd
CY2024Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-5768 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2040783 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7832594 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5121650 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1860 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
10630 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
8909530 usd
CY2023Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
5370 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2183507 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11865533 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2040783 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2183507 usd
CY2023Q1 hoth Research And Developmentlicenses Acquired Expensed
ResearchAndDevelopmentlicensesAcquiredExpensed
8125 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
513350 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10630 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-18803 usd
CY2024Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-581 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
157799 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
96244 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-39305 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-47225 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1723956 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2289418 usd
CY2023Q1 hoth Proceeds From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net
ProceedsFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNet
8909530 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1860 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8911390 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1723956 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6621972 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5768 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-6201 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9292352 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6428611 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7562628 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13044382 usd
CY2024Q1 hoth Increase In Deferred Offering Cost And Additional Paidin Capital
IncreaseInDeferredOfferingCostAndAdditionalPaidinCapital
550500 usd
CY2024Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-05-16
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7600000 usd
CY2024Q2 hoth Warrants Purchase To Shares
WarrantsPurchaseToShares
2500000 shares
CY2024Q2 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
1.6775
CY2024Q2 hoth Net Proceeds After Deduction
NetProceedsAfterDeduction
4200000 usd
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain line items on the condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2023 have been reclassified to conform to the current period presentation. Research and development - licenses acquired (including stock-based compensation) of $48,033 was reclassified to research and development. Compensation and related expenses (including stock-based compensation) of $295,564, professional fees (including stock-based compensation) of $616,375, rent of $15,120, and other general and administrative expense of $326,880 were consolidated into one general and administrative line item. These reclassifications did not change our reported net loss or comprehensive loss for the three months ended March 31, 2023.</p>
CY2024Q1 hoth Compensation And Related Expenses
CompensationAndRelatedExpenses
295564 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
616375 usd
CY2024Q1 us-gaap Prepaid Rent
PrepaidRent
15120 usd
CY2024Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
326880 usd
CY2024Q1 us-gaap Revenues
Revenues
1235000000 usd
CY2024Q1 us-gaap Convertible Debt
ConvertibleDebt
1000000000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation, the valuation of modified warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations may be affected. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7562628 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9292352 usd
CY2024Q1 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
100000 usd
CY2023 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
100000 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of credit risk and off-balance sheet risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has significant cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p>
CY2024Q1 us-gaap Interest Income Federal Funds Sold
InterestIncomeFederalFundsSold
250000 usd
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4455903 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3110875 shares
CY2024Q1 hoth Schedule Of Research And Development Expenses For Licenses Acquired
ScheduleOfResearchAndDevelopmentExpensesForLicensesAcquired
<span style="font-family: Times New Roman, Times, Serif">The following summarizes the Company’s research and development expenses for licenses acquired </span> <span style="font-family: Times New Roman, Times, Serif">during the three months ended March 31, 2024 and 2023:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,158</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">North Carolina State University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">University of Cincinnati</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,812</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">48,033</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
2812 usd
CY2023Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
48033 usd
CY2024Q1 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
36819 usd
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
37400 usd
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.17
CY2024Q2 us-gaap Shares Issued
SharesIssued
79 shares
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0036
CY2024Q1 us-gaap Other Investments
OtherInvestments
36819 usd
CY2023Q4 us-gaap Other Investments
OtherInvestments
37400 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 hoth Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3000000 shares
CY2023Q4 hoth Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3000000 shares
CY2024Q1 hoth Exercise Of Pre Funded Warrants
ExerciseOfPreFundedWarrants
55675 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1693 shares
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.16
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1693 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.16
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1878 usd
CY2024Q1 hoth Unrecognized Stockbased Compensation Term
UnrecognizedStockbasedCompensationTerm
P0Y9M
CY2024Q1 hoth Directors To Purchase Shares
DirectorsToPurchaseShares
450000 shares
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense
StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
512685 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.36
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.20 pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0402 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
169362 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.78
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P8Y4M24D
CY2024Q1 us-gaap Stock Issued During Period Shares Employee Stock Ownership Plan
StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
450000 shares
CY2024Q1 hoth Share Based Compensation Arrangements By Share Based Payment Award Options Weighted Average Exercise Price Employee Options Issued
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceEmployeeOptionsIssued
1.36
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
147
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
617362 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.86
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P9Y4M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
617362 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.86
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y4M24D
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
513350 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10630 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
513350 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10630 usd
CY2024Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
1.6775
CY2024Q1 hoth Deducting Placement Agent Fees
DeductingPlacementAgentFees
4200000
CY2024Q1 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-07-03
CY2024Q2 hoth Placement Agent Warrant
PlacementAgentWarrant
125000 shares
CY2024Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
3750000 shares
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
550500 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.098 pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0418 pure
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
8617 usd
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4653 usd
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
15120 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
13270 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
15120 usd
CY2024Q1 hoth Right Of Use Asset Gross
RightOfUseAssetGross
59698 usd
CY2023Q4 hoth Right Of Use Asset Gross
RightOfUseAssetGross
59698 usd
CY2024Q1 hoth Accumulated Amortizationof Rightof Use Assets
AccumulatedAmortizationofRightofUseAssets
11476 usd
CY2023Q4 hoth Accumulated Amortizationof Rightof Use Assets
AccumulatedAmortizationofRightofUseAssets
4533 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48222 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55165 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
29321 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
28839 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18901 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26326 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
48222 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
55165 usd
CY2024Q1 us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
8196 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M
CY2023 hoth Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.10 pure
CY2024Q1 hoth Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.10 pure
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
32784 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
19124 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
51908 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3686 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
48222 usd
CY2024Q1 us-gaap Shares Issued
SharesIssued
125000 shares
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CY2024Q1 hoth Research And Developmentlicenses Acquired Expensed
ResearchAndDevelopmentlicensesAcquiredExpensed
usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
CY2023Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
usd
CY2024Q1 hoth Proceeds From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net
ProceedsFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNet
usd
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 hoth Increase In Deferred Offering Cost And Additional Paidin Capital
IncreaseInDeferredOfferingCostAndAdditionalPaidinCapital
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q1 hoth Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Employee Options Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueEmployeeOptionsIssued
usd
CY2024Q1 hoth Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Lifein Years Employee Options Issued
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeinYearsEmployeeOptionsIssued
CY2024Q1 hoth Share Based Compensation Arrangement By Share Based Payment Award Options Total Intrinsic Value Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsTotalIntrinsicValueExpired
usd
CY2024Q1 hoth Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Lifein Years Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeinYearsExpired
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
usd
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001711786

Files In Submission

Name View Source Status
0001213900-24-042906-index-headers.html Edgar Link pending
0001213900-24-042906-index.html Edgar Link pending
0001213900-24-042906.txt Edgar Link pending
0001213900-24-042906-xbrl.zip Edgar Link pending
ea0204707-10q_hoththerap.htm Edgar Link pending
ea020470701ex31-1_hoththerap.htm Edgar Link pending
ea020470701ex31-2_hoththerap.htm Edgar Link pending
ea020470701ex32-1_hoththerap.htm Edgar Link pending
ea020470701ex32-2_hoththerap.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hoth-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hoth-20240331_cal.xml Edgar Link unprocessable
hoth-20240331_def.xml Edgar Link unprocessable
hoth-20240331_lab.xml Edgar Link unprocessable
hoth-20240331_pre.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ea0204707-10q_hoththerap_htm.xml Edgar Link completed